DBV Technologies Reports Positive VITESSE Data, Expands Peanut Allergy Study to Infants
Event summary
- DBV Technologies to present positive Phase 3 VITESSE study data at EAACI Congress 2026, showing statistically significant efficacy of VIASKIN® Peanut Patch in children with peanut allergy and atopic comorbidities.
- VIASKIN® Peanut Patch demonstrated 48.3% efficacy in children with asthma, 46.8% in those with other food allergies, and 47.2% in those with atopic dermatitis, compared to placebo.
- Company to preview Phase 2 THRIVE study design, assessing efficacy and safety of VIASKIN® Peanut Patch in infants aged 6-12 months with peanut allergy.
- THRIVE study aims to evaluate whether infants can achieve ad lib consumption of peanuts after three years of treatment with VIASKIN® Peanut Patch.
The big picture
DBV Technologies' positive VITESSE study data and expansion into infant peanut allergy treatment highlight the growing focus on early intervention in allergy management. The company's VIASKIN® Peanut Patch represents a non-invasive approach to peanut allergy treatment, addressing a significant unmet medical need in both children and infants. The strategic shift towards younger patient populations could position DBV Technologies as a leader in pediatric allergy treatment, provided the THRIVE study yields positive results.
What we're watching
- Clinical Efficacy
- How the VIASKIN® Peanut Patch's demonstrated efficacy in children with atopic comorbidities will impact regulatory approval prospects.
- Market Expansion
- Whether DBV Technologies can successfully position the VIASKIN® Peanut Patch as a treatment option for infants, a previously underserved demographic.
- Competitive Landscape
- The pace at which DBV Technologies can differentiate itself from competitors in the peanut allergy treatment space.
Related topics